UNSPSC 51382600: Nonsteroidal anti inflammatory carbamates

Nonsteroidal anti inflammatory drugs made from derivatives of carbamic acid, H2NC(=O)OH, such as N-substituted and O-substituted carbamic acids.

UNSPSC 51382600 Nonsteroidal anti-inflammatory carbamates is a Class code that shows minimal recent activity aligned with its nominal scope. The three recent state and local opportunities posted under this code do not purchase nonsteroidal anti-inflammatory carbamates; instead, they solicit naloxone and drug deactivation systems (Seminole County, Florida), direct-to-manufacturer prescription fulfillment capabilities (Texas Health and Human Services Commission), and generic multi-source pharmaceuticals and OTC products broadly (Minnesota Multistate Cooperative Purchasing Alliance). The mismatch between the code's name and the actual work being bought suggests that state and local procurement offices are applying this code to pharmaceutical and health-product categories that fall well outside its intended definition. Absent recent opportunities that actually align with nonsteroidal anti-inflammatory carbamates, this code shows little actionable purchasing activity for vendors in that product line.

The issuing bodies soliciting under this code include county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and cooperative purchasing alliances serving multi-state and multi-jurisdiction networks (Minnesota MMCAP, which serves Oregon as well). The geographic spread covers Florida, Texas, and Minnesota-Oregon. Representative opportunities include Seminole County's IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually with a due date of July 26, 2023 (note: the posted date of June 30, 2026 conflicts with the 2023 deadline, indicating a data anomaly); Texas HHS Commission's RFI posted April 3, 2026 seeking vendor capabilities for direct-to-manufacturer prescription programs; and Minnesota MMCAP's RFP posted January 20, 2026 with a due date of March 26, 2026 for generic pharmaceutical and OTC product supply through authorized wholesalers.